Biographical Sketch
Randall Starling, MD, MPH, is Head of the Section of Heart Failure and Cardiac Transplant Medicine, the Medical Director of the Kaufman Center for Heart Failure and a Staff Cardiologist in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine. He also serves as Vice Chairman of Cardiovascular Medicine, Operations. He specializes in congestive heart failure, cardiac transplantation, cardiomyopathy and mechanical circulatory support devices. Dr. Starling was appointed to the Cleveland Clinic in 1995 as a Staff Physician and Director of the Heart Transplant Medical Services. He has a joint appointment as a Staff Physician in Cleveland Clinic’s Multi-Organ Transplant Center. He is board-certified as a Diplomate in internal medicine and in the subspecialty of cardiovascular disease. In addition, he is certified by the National Board of Medical Examiners.
Dr. Starling did his undergraduate work in biology, graduating cum laude from the University of Pittsburgh. He continued his education at the University of Pittsburgh School of Public Health, where he graduated summa cum laude with a Master’s Degree in Public Health. He received his medical training at Temple University where he was an Honor Graduate, was inducted into the Alpha Omega Alpha medical honor society and was awarded the Mosby Book Scholarship. He returned to the University of Pittsburgh Medical Center to complete his internship and residency in internal medicine.
During the course of his clinical training and association with the University of Pittsburgh Medical Center, Dr. Starling became Chief Medical Resident, Instructor in Medicine and Medical Director of the cardiac transplant program. Dr. Starling completed a fellowship in cardiology from the Ohio State University (OSU). During the course of his association with OSU, Dr. Starling became an Associate Professor of Medicine and Medical Director of the OSU Cardiac Transplant Program.
Dr Starling has been a principal or co-principal investigator on numerous clinical trials, including National Institutes of Health (NIH) grant-funded trials and numerous industry-sponsored trials. He conducted many other research trials including multicenter, randomized trials related to cardiac transplantation and heart failure. He has particular interest in devices and other forms of surgical therapy for heart failure.
He has published articles in a broad spectrum of scientific and professional journals and authored numerous chapters in medical textbooks. He sits on the Editorial Board of the Journal of the American College of Cardiology. Dr. Starling is a reviewer and editorial consultant for numerous other journals. He is Editor of the chapter on Heart Failure in the American College of Cardiology Self Assessment Program (ACCSAP VI). He has served as an editorial consultant on ABC’s “20/20,” CNN’s “Heroes in Medicine” and several PBS televised programs. He was named to Best Doctors in America in 2002, 2003-2004, and 2005-2007 editions.
Dr. Starling is a Fellow in the American College of Cardiology and a member of the American Heart Association Council on Clinical Cardiology, the American Society of Transplantation, the Heart Failure Society of America and the International Society for Heart and Lung Transplantation, where he serves on the Board of Directors and is Program Chair for the 2009 meeting.
Specialty Interests
heart failure, cardiomyopathy, cardiac transplantation, mechanical circulatory support devices
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 8/3/2008, Dr.
Starling has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Starling receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
Medtronic, Inc.
Equity. Dr. Starling owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:
CardioMEMS, Inc.
